TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34676600

Group type: EXPERIMENTAL
Intervention: Thiamidol (applied daily in Dual Serum followed by Day Care SPF30 or Night Care)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Thiamidol
Number of subjects: 48

Group type: COMPARATOR
Intervention: Vehicle (applied daily in corresponding vehicle formulations)
Number of subjects: 48
Study: 35331406

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 5988

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5988
Study: 33210408

Group type: EXPERIMENTAL
Intervention: Curcumagalactomannosides (CGM) 400 mg once daily
Number of subjects: 72

Group type: COMPARATOR
Intervention: Glucosamine hydrochloride (GLN) 500 mg and Chondroitin sulphate (CHN) 415 mg, supplied as a single oral dose twice a day
Number of subjects: 72
Study: 34102278

Group type: EXPERIMENTAL
Intervention: Dance therapy intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Music therapy intervention
Number of subjects: 0
Study: 37793976

Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: PCV15
Number of subjects: 87
Study: 34309766

Group type: EXPERIMENTAL
Intervention: Whole-body MRI with diffusion-weighted imaging (DWIBS)
Number of subjects: 52
Study: 32251871

Group type: EXPERIMENTAL
Intervention: Brain death exposure
Number of subjects: 1072

Group type: EXPERIMENTAL
Intervention: Circulatory death exposure
Number of subjects: 1072
Study: 35421449

Group type: EXPERIMENTAL
Intervention: mRNA-1273 COVID-19 vaccine
Number of subjects: 505
Study: 33561279

Group type: EXPERIMENTAL
Intervention: Alternating Current (AC) at 2.5 kHz, pulse duration = 0.4 milliseconds, burst frequency = 100 Hz
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pulsed Current (PC), pulse duration = 2 milliseconds, pulse frequency = 100 Hz
Number of subjects: 30
Study: 32623925

Group type: EXPERIMENTAL
Intervention: Genetically predicted mean arterial pressure (MAP)
Number of subjects: 408228

Group type: EXPERIMENTAL
Intervention: Genetically predicted pulse pressure (PP)
Number of subjects: 408228

Group type: EXPERIMENTAL
Intervention: Genetically predicted MAP
Number of subjects: 408228

Group type: EXPERIMENTAL
Intervention: Genetically predicted PP
Number of subjects: 408228

Group type: EXPERIMENTAL
Intervention: Genetically predicted MAP and PP
Number of subjects: 408228
Study: 35915733

Group type: EXPERIMENTAL
Intervention: Acupuncture along meridians
Number of subjects: 96

Group type: COMPARATOR
Intervention: Conventional western medicine and massage therapy
Number of subjects: 96
Study: 33882526

Group type: EXPERIMENTAL
Intervention: Carboplatin plus paclitaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triplet chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (single agents or in combination)
Number of subjects: 0
Study: 34463423

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 14543

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14543
Study: 34127033

Group type: EXPERIMENTAL
Intervention: Enhanced information group (standard information plus video)
Number of subjects: 521

Group type: COMPARATOR
Intervention: Standard information group (patient information and diagrams)
Number of subjects: 521
Study: 32638504

Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 947

Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 947

Group type: COMPARATOR
Intervention: MTX (7.5-20 mg/week)
Number of subjects: 947
Study: 35870875

Group type: EXPERIMENTAL
Intervention: Individualized Vivifrail multicomponent exercise program and personalized executive function-based cognitive training (VIVIFRAIL-COGN)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Usual care delivered in the Falls Units, including the Otago Exercise Program
Number of subjects: 320
Study: 33773984

Group type: EXPERIMENTAL
Intervention: Dexamethasone intracanalicular insert
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo insert
Number of subjects: 30
Study: 33105375

Group type: EXPERIMENTAL
Intervention: Linear LIST
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nonlinear LIST
Number of subjects: 8

Group type: COMPARATOR
Intervention: Both conditions
Number of subjects: 8
Study: 34020578

Group type: EXPERIMENTAL
Intervention: Letrozole (LTZ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (laparoscopy alone)
Number of subjects: 0
Study: 33298617

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 195

Group type: COMPARATOR
Intervention: Nontocilizumab
Number of subjects: 195
Study: 35676287

Group type: EXPERIMENTAL
Intervention: Exercise Training (ET) 3 times/week
Number of subjects: 47

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 47
Study: 34390504

Group type: EXPERIMENTAL
Intervention: Low-dose thymoglobulin (2.5 mg/kg)
Number of subjects: 120
Study: 32107560

Group type: EXPERIMENTAL
Intervention: Atacicept 150 mg
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study: 35256000

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Usual care and independent exercise with a single therapy session
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Usual care and supervised exercise with three therapy sessions over 12 weeks
Number of subjects: 72
Study: 33083903

Group type: EXPERIMENTAL
Intervention: Metasul bearings
Number of subjects: 250

Group type: COMPARATOR
Intervention: Cerasul bearings
Number of subjects: 250
Study: 32586366

Group type: EXPERIMENTAL
Intervention: Low-dose UC-MSCs (3 × 10^6 cells)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: High-dose UC-MSCs (6 × 10^6 cells)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 32727681

Group type: EXPERIMENTAL
Intervention: Sutureless valve
Number of subjects: 291
Study: 32542725

Group type: EXPERIMENTAL
Intervention: Connective Tissue Graft (CTG)
Number of subjects: 42

Group type: COMPARATOR
Intervention: No Connective Tissue Graft (Control)
Number of subjects: 42
Study: 35059929

Group type: EXPERIMENTAL
Intervention: PRK surgery
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Higher baseline IOP
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Higher baseline CCT
Number of subjects: 348
Study: 34490798

Group type: EXPERIMENTAL
Intervention: Class II malocclusion group
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Overall ratio values among malocclusion groups
Number of subjects: 252
Study: 35727433

Group type: EXPERIMENTAL
Intervention: high-resolution digital PET (dPET)
Number of subjects: 212

Group type: COMPARATOR
Intervention: high-resolution conventional PET (cPET)
Number of subjects: 212
Study: 34464782

Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Number of subjects: 80

Group type: COMPARATOR
Intervention: S-1
Number of subjects: 80
Study: 32527283

Group type: EXPERIMENTAL
Intervention: Standard BP target group (140 to < 150 mmHg)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Moderately intensive BP target group (130 to < 140 mmHg)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Intensive BP target group (< 130 mmHg)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as the standard treatment)
Number of subjects: 105
Study: 36052462

Group type: EXPERIMENTAL
Intervention: Wisepill electronic monitoring (EM)
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Self-report (SR)
Number of subjects: 702

Group type: COMPARATOR
Intervention: Control arm (Self-report vs Wisepill)
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 702
Study: 34425204

Group type: EXPERIMENTAL
Intervention: Traditional resistance training
Number of subjects: 38

Group type: COMPARATOR
Intervention: Elastic tubes training
Number of subjects: 38
Study: 35420730

Group type: EXPERIMENTAL
Intervention: Hybrid convergent procedure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endocardial catheter ablation
Number of subjects: 0
Study: 34700212

Group type: EXPERIMENTAL
Intervention: KarXT (a fixed combination of xanomeline and trospium chloride)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Blinded site-independent PANSS ratings
Number of subjects: 148
Study: 33167954

Group type: EXPERIMENTAL
Intervention: Zirconia crowns
Number of subjects: 120

Group type: COMPARATOR
Intervention: Strip crowns
Number of subjects: 120
Study: 36356596

Group type: EXPERIMENTAL
Intervention: VBN-rEBUS-GS without fluoroscopy
Number of subjects: 426

Group type: COMPARATOR
Intervention: VBN-rEBUS-GS with fluoroscopy
Number of subjects: 426
Study: 33412611

Group type: EXPERIMENTAL
Intervention: Selatogrel (16 mg subcutaneous) + Clopidogrel (300 or 600 mg, 30 minutes after selatogrel)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Selatogrel (16 mg subcutaneous) + Prasugrel (60 mg, 30 minutes after selatogrel)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Selatogrel (16 mg subcutaneous) + Prasugrel (60 mg, 12 hours after selatogrel)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Selatogrel (16 mg subcutaneous) + Clopidogrel (300 or 600 mg, 12 hours after selatogrel)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Selatogrel (16 mg subcutaneous) + Ticagrelor (180 mg, 30 minutes after selatogrel)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo + Clopidogrel (300 or 600 mg, 30 minutes after placebo)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo + Prasugrel (60 mg, 30 minutes after placebo)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo + Ticagrelor (180 mg, 30 minutes after placebo)
Number of subjects: 72
Study: 32364618

Group type: EXPERIMENTAL
Intervention: P+P intervention for 2° Cardiac Arrest group
Number of subjects: 301

Group type: COMPARATOR
Intervention: 1o No CRT group
Number of subjects: 301
Study: 35997854

Group type: EXPERIMENTAL
Intervention: Inpatient SDM
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Inpatient SDM + CHW-navigation
Number of subjects: 52

Group type: COMPARATOR
Intervention: Comparator (furnishing of LCS decision aid only)
Number of subjects: 52
Study: 32356286

Group type: EXPERIMENTAL
Intervention: CORDIS group treatment program (10-week modularized treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32420973

Group type: EXPERIMENTAL
Intervention: Lertal® (nutraceutical)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 0
Study: 35445641

Group type: EXPERIMENTAL
Intervention: MenACYW-TT
Number of subjects: 701

Group type: COMPARATOR
Intervention: MCV4-TT
Number of subjects: 701

Group type: COMPARATOR
Intervention: MenC-TT
Number of subjects: 701
Study: 34087690

Group type: EXPERIMENTAL
Intervention: Secure CBM‐I training
Number of subjects: 80

Group type: COMPARATOR
Intervention: Insecure CBM‐I training
Number of subjects: 80
Study: 35358461

Group type: EXPERIMENTAL
Intervention: Screening spinal MRI and pre‐emptive treatment for spinal cord compression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study: 33741514

Group type: COMPARATOR
Intervention: Collective debriefing (1 debriefing by 6 pairs)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Individual debriefing (1 debriefing by pair)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Collective debriefing
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Individual debriefing
Number of subjects: 44
Study: 35842575

Group type: EXPERIMENTAL
Intervention: Remimazolam
Number of subjects: 165

Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 165
Study: 33792550

Group type: EXPERIMENTAL
Intervention: Patchy-type 12-lead ECG (P-ECG)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional 12-lead ECG (C-ECG)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: P-ECG
Number of subjects: 18
Study: 32306007

Group type: EXPERIMENTAL
Intervention: Oral pyrotinib (400 mg once daily or 320 mg)
Number of subjects: 72
Study: 36434692

Group type: EXPERIMENTAL
Intervention: Yokukansan
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study: 33048289

Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD) group
Number of subjects: 210

Group type: COMPARATOR
Intervention: Non-hemodialysis (non-HD) group
Number of subjects: 210
Study: 36498485

Group type: EXPERIMENTAL
Intervention: Scotchbond™ Universal (SBU) in self-etch (SE) mode
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Scotchbond™ Universal (SBU) in etch-and-rinse (ER) mode
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Scotchbond™ Universal (SBU) in selective-enamel-etch (SEE) mode
Number of subjects: 22

Group type: COMPARATOR
Intervention: OptiBond™ FL (OFL) as control
Number of subjects: 22
Study: 33340343

Group type: EXPERIMENTAL
Intervention: Cefprozil for suspension (125 mg) under fasted conditions
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cefprozil for suspension (125 mg) under fed conditions
Number of subjects: 60

Group type: COMPARATOR
Intervention: Granule formulation of cefprozil
Number of subjects: 60
Study: 34979962

Group type: EXPERIMENTAL
Intervention: Stepped-dose furosemide (SF) - continuous infusion of furosemide 100 mg on day 1, with daily incremental doses to 200 mg, 300 mg, and 400 mg.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Combined diuretics (CD) - combination of oral chlorthalidone 50 mg, spironolactone 50 mg, and infusion of furosemide 100 mg for 4 consecutive days.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Both SF and CD groups.
Number of subjects: 80
Study: 34738551

Group type: EXPERIMENTAL
Intervention: Nicorandil (24 mg/d intravenously for 1 week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study: 32741784

Group type: EXPERIMENTAL
Intervention: Treadmill training (TT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Treadmill training (TT) + Whole body vibration training (WBVT)
Number of subjects: 30
Study: 35851689

Group type: EXPERIMENTAL
Intervention: Metronidazole (MTZ) + Amoxicillin (AMX)
Number of subjects: 656

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 656
Study: 32543706

Group type: EXPERIMENTAL
Intervention: rhBMP6/ABC (1.0 mg/10 mL ABC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (10 mL ABC containing excipients)
Number of subjects: 20
Study: 36384686

Group type: EXPERIMENTAL
Intervention: ChloraPrep (2% chlorhexidine gluconate and 70% isopropyl alcohol)
Number of subjects: 105

Group type: COMPARATOR
Intervention: DuraPrep (0.7% iodophor and 74% isopropyl alcohol)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Both ChloraPrep and DuraPrep
Number of subjects: 105
Study: 33176593

Group type: EXPERIMENTAL
Intervention: 30 minutes of NMES daily (Group B)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 60 minutes of NMES daily (Group C)
Number of subjects: 76

Group type: COMPARATOR
Intervention: No NMES (Group A)
Number of subjects: 76
Study: 35710669

Group type: EXPERIMENTAL
Intervention: Sugar‐Coated Science (SCS)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Both SCS and DCT
Number of subjects: 92
Study: 34380540

Group type: EXPERIMENTAL
Intervention: 3D printed model
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional 2D diagram
Number of subjects: 40
Study: 35580859

Group type: EXPERIMENTAL
Intervention: 8-week low-calorie diet (800 kcal/day)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Liraglutide (GLP-1 analogue) with habitual activity
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Exercise training and placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Liraglutide in combination with exercise training
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo and habitual activity
Number of subjects: 56
Study: 34347314

Group type: EXPERIMENTAL
Intervention: NLP modules for assessing comorbidities
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: NLP modules for assessing diabetes
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: NLP modules for assessing hypertension
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: NLP modules for assessing myocardial infarction
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: NLP modules for assessing embolic stroke
Number of subjects: 1000
Study: 35006243

Group type: EXPERIMENTAL
Intervention: Intensive treatment (<120 mm Hg)
Number of subjects: 8556

Group type: COMPARATOR
Intervention: Standard treatment (<140 mm Hg)
Number of subjects: 8556

Group type: COMPARATOR
Intervention: Standard treatment vs non-Hispanic Black
Number of subjects: 8556

Group type: EXPERIMENTAL
Intervention: Intensive treatment vs non-Hispanic Black
Number of subjects: 8556

Group type: COMPARATOR
Intervention: Standard treatment vs Hispanic
Number of subjects: 8556

Group type: EXPERIMENTAL
Intervention: Intensive treatment vs Hispanic
Number of subjects: 8556
Study: 33828354

Group type: EXPERIMENTAL
Intervention: Criminal Justice (CJ) mandated treatment
Number of subjects: 161

Group type: COMPARATOR
Intervention: Child Protective Services (CPS) mandated treatment
Number of subjects: 161

Group type: COMPARATOR
Intervention: Nonmandated treatment
Number of subjects: 161
Study: 35149566

Group type: EXPERIMENTAL
Intervention: Elobixibat (an ileal bile acid transporter inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33750593

Group type: EXPERIMENTAL
Intervention: Personalized text messages from pharmacists (SMS group)
Number of subjects: 499

Group type: COMPARATOR
Intervention: Standard care alone (control group)
Number of subjects: 499
Study: 32678484

Group type: EXPERIMENTAL
Intervention: Motivational questions (Study 1: 4 questions; Study 2: 6 questions)
Number of subjects: 9999

Group type: EXPERIMENTAL
Intervention: Motivational questions (Study 2: 6 questions)
Number of subjects: 9999

Group type: COMPARATOR
Intervention: No-question control
Number of subjects: 9999
Study: 34081249

Group type: EXPERIMENTAL
Intervention: Needle Knife Papillotomy (NKP)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Needle Knife Fistulotomy (NKF)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Both NKP and NKF
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: NKP
Number of subjects: 188

Group type: COMPARATOR
Intervention: NKF
Number of subjects: 188
Study: 35186445

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 75

Group type: COMPARATOR
Intervention: PTSD+ participants
Number of subjects: 75

Group type: COMPARATOR
Intervention: PTSD− participants
Number of subjects: 75
Study: 35676397

Group type: EXPERIMENTAL
Intervention: Sialylated HMOs
Number of subjects: 45

Group type: COMPARATOR
Intervention: Fucosylated or undecorated HMOs
Number of subjects: 45
Study: 33656107

Group type: EXPERIMENTAL
Intervention: Stroke realistic simulation course
Number of subjects: 17

Group type: COMPARATOR
Intervention: Neurosonology course
Number of subjects: 17

Group type: COMPARATOR
Intervention: Emergency Neurologic Life Support (ENLS) course
Number of subjects: 17
Study: 32968823

Group type: EXPERIMENTAL
Intervention: Standardized template for re-interpretation MSK reports
Number of subjects: 1052
Study: 36335077

Group type: EXPERIMENTAL
Intervention: High ligation (HL) of the inferior mesenteric artery (IMA)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Low ligation (LL) of the inferior mesenteric artery (IMA)
Number of subjects: 196
Study: 34840585

Group type: EXPERIMENTAL
Intervention: Acupotomy based on the meridian-sinew theory
Number of subjects: 124

Group type: COMPARATOR
Intervention: Acupotomy based on anatomy
Number of subjects: 124
Study: 35839335

Group type: EXPERIMENTAL
Intervention: Risankizumab (RZB) after switching from adalimumab (ADA)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Risankizumab (RZB) after switching from ustekinumab (UST)
Number of subjects: 225
Study: 32103441

Group type: EXPERIMENTAL
Intervention: Formal advance care planning (ACP) program
Number of subjects: 282

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Patient-surrogate discussion of care preference
Number of subjects: 282
Study: 36346050

Group type: EXPERIMENTAL
Intervention: Orsiro sirolimus‐eluting stents (SES)
Number of subjects: 3514

Group type: EXPERIMENTAL
Intervention: Synergy everolimus‐eluting stents (EES)
Number of subjects: 3514

Group type: COMPARATOR
Intervention: Resolute Integrity zotarolimus‐eluting stents (ZES)
Number of subjects: 3514

Group type: EXPERIMENTAL
Intervention: SES in patients with diabetes
Number of subjects: 3514

Group type: EXPERIMENTAL
Intervention: EES in patients with diabetes
Number of subjects: 3514

Group type: COMPARATOR
Intervention: ZES in patients with diabetes
Number of subjects: 3514
Study: 35987909

Group type: EXPERIMENTAL
Intervention: Glabellar botulinum toxin (BTX) injections
Number of subjects: 45

Group type: COMPARATOR
Intervention: Serial acupuncture (ACU) of the head
Number of subjects: 45
Study: 32125188

Group type: EXPERIMENTAL
Intervention: Enalapril treatment
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 36345180

Group type: EXPERIMENTAL
Intervention: DHS with TSP
Number of subjects: 68

Group type: COMPARATOR
Intervention: Short PFN
Number of subjects: 68
Study: 35074904

Group type: EXPERIMENTAL
Intervention: Ipilimumab
Number of subjects: 1699

Group type: COMPARATOR
Intervention: High-dose interferon-alfa (HDI)
Number of subjects: 1699

Group type: EXPERIMENTAL
Intervention: Gene expression profiling (GEP)
Number of subjects: 1699

Group type: EXPERIMENTAL
Intervention: Circulating biomarkers
Number of subjects: 1699
Study: 34120628

Group type: COMPARATOR
Intervention: Conservative treatment (knee brace and outpatient physical therapy)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Tailored patella stabilizing surgical treatment
Number of subjects: 128
Study: 35275531

Group type: EXPERIMENTAL
Intervention: Self-reported physical activity following WHO recommendations
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Accelerometry values confirming adherence to WHO recommendations
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Education and accelerometry values in accordance with WHO recommendations
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Accelerometry results
Number of subjects: 104
Study: 34481117

Group type: EXPERIMENTAL
Intervention: Ultrasomics model
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Clinical model
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Combined model
Number of subjects: 193
Study: 32916339

Group type: EXPERIMENTAL
Intervention: Respiratory rehabilitation program
Number of subjects: 28

Group type: COMPARATOR
Intervention: Routine nursing care (Control)
Number of subjects: 28